SCHEMBL6773700

SCHEMBL6773700

NC(Cc1cn(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 13/20 0.49
ALPI P09923 1/20 0.44
PKM P14618 1/20 0.44
PTGS1 P23219 1/20 0.44
XIAP P98170 1/20 0.44
SLC7A5 Q01650 1/20 0.44
CYP1A2 P05177 1/20 0.43
KIF11 P52732 3/20 0.42
CPB1 P15086 1/20 0.40
CPB2 Q96IY4 1/20 0.40
PTPN1 P18031 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21690129 1.00 SIRT2 (0.49) SIRT2ALPIPKMPTGS1XIAP
SCHEMBL3839522 1.00 SIRT2 (0.49) SIRT2ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL6326997 0.99 SIRT2 (0.48) SIRT2ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL27994024 0.99 SIRT2 (0.48) SIRT2ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL21176269 0.99 SIRT2 (0.48) SIRT2ALPIPKMPTGS1XIAP
SCHEMBL21095860 0.94 KIF11 (0.48) SIRT2ALPIPKMPTGS1XIAP
SCHEMBL21095861 0.93 KIF11 (0.49) SIRT2KIF11
SCHEMBL31404225 0.91 SIRT2 (0.48) SIRT2KIF11CPB1CPB2
SCHEMBL21096113 0.90 KIF11 (0.52) SIRT2KIF11
SCHEMBL522051 0.86 SIRT2 (0.60) SIRT2KIF11CPB1CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024316-A 2, 4-binitro-6-phenyl-phenylthio protecting group and polypeptide synthesis method thereof 南开大学 2023-11-10 CN claimed
EP-3970796-B1 COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS STABILIZED PACAP PEPTIDE SENJU PHARMA CO (JP) 2025-08-20 EP disclosed
US-12304932-B2 PACAP stabilized peptide SENJU PHARMACEUTICAL CO., LTD. (JP) 2025-05-20 US disclosed
CN-111344300-B Stabilizing peptides of PACAP 千寿制药株式会社 2024-08-30 CN disclosed
US-20240200049-A1 COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS YALE UNIVERSITY 2024-06-20 US disclosed
US-20240140935-A1 NON-COVALENT DIMER CATION, SALT THEREOF, PREPARATION METHOD THEREOF, AND USE THEREOF AS ANTIOXIDANT SUZHOU PROTONATION CHAIN BIOTECHNOLOGY CO., LTD. (CN) 2024-05-02 US disclosed
CN-117024316-A 2, 4-binitro-6-phenyl-phenylthio protecting group and polypeptide synthesis method thereof 南开大学 2023-11-10 CN disclosed
CN-110746355-B Phenylpyrazole compound, pharmaceutical composition, and preparation method and application thereof 中国科学院上海有机化学研究所 2023-08-11 CN disclosed
US-11649446-B2 Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids YALE UNIVERSITY (US) 2023-05-16 US disclosed
CN-116082565-A Self-assembled oxidation mimic enzyme material and preparation method and application thereof 北京化工大学 2023-05-09 CN disclosed
US-20030055086-A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors LES LABORATOIRES SERVIER (FR) 2003-03-20 US disclosed
US-5830868-A Substituted DI- and tripeptide inhibitors of protein: farnesyl transferase WARNER-LAMBERT COMPANY (US) 1998-11-03 US disclosed
US-5763577-A ANTICARCINOGENIC AGENTS WARNER-LAMBERT COMPANY (US) 1998-06-09 US disclosed
EP-0767800-A1 HISTIDINE AND HOMOHISTIDINE DERIVATIVES AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE WARNER-LAMBERT COMPANY (US) 1997-04-16 EP disclosed
EP-0730605-A1 SUBSTITUTED DI- AND TRIPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 1996-09-11 EP disclosed
EP-0725790-A1 SUBSTITUTED TETRA- AND PENTAPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE PARKE DAVIS & COMPANY (US) 1996-08-14 EP disclosed
WO-1996017861-A1 SUBSTITUTED TETRA- AND PENTAPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 1996-06-13 WO disclosed
WO-1996000736-A1 HISTIDINE AND HOMOHISTIDINE DERIVATIVES AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE WARNER-LAMBERT COMPANY (US) 1996-01-11 WO disclosed
WO-1995012612-A1 SUBSTITUTED DI- AND TRIPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 1995-05-11 WO disclosed
WO-1995011917-A1 SUBSTITUTED TETRA- AND PENTAPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE PARKE, DAVIS & COMPANY (US) 1995-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12304932-B2 PACAP stabilized peptide VIP, DNPEP, SCTR SIRT2 2759/4885ALPI 4217/4885PKM 3059/4885
US-20240140935-A1 NON-COVALENT DIMER CATION, SALT THEREOF, PREPARATION METHOD THEREOF, AND USE THEREOF AS ANTIOXIDANT SLC10A1, CYP11B1, CYP11B2 SIRT2 728/4885ALPI 903/4885PKM 1245/4885
US-20030055086-A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors MME, ACE, ECE1 SIRT2 3453/4885ALPI 3216/4885PKM 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.